<DOC>
	<DOCNO>NCT00987142</DOCNO>
	<brief_summary>A phase II , comparative , open label , prospective , multicentre clinical trial patient undergo two procedure ; implant patch culture chimeric skin ( experimental therapy ) half skin lesion occlusive non-adherent dressing ( control ) half 12 month follow-up two Spanish centre .</brief_summary>
	<brief_title>Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa</brief_title>
	<detailed_description>Reconstruction interdigital commisures patient severe skin syndactyly use laminar graft uniformly systematically take electrical compress air dermatome aseptic area extent depth micron patient . Immediately surgical procedure , patch culture chimeric skin ( experimental therapy ) implant half skin defect patient , occlusive non - adherent dressing ( control ) implant half . Patients initially follow every two day epithelisation occur ( approximately 21 day surgery ) 3,8 , 12 month follow-up .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>Inclusion criterion : Patients sex 28 day age . Patients recessive dystrophic epidermolysis bullosa diagnose clinical historical criterion severe skin syndactyly reconstructive surgery indicate . Patients whose legal guardian give write informed consent participation study study procedure perform . Patients age ≥ 12 year give write informed consent participation study study procedure perform . Exclusion criterion : Women childbearing age use effective contraceptive method ( oral contraception ) Pregnant nurse woman Documented suspected hypersensitivity therapeutic agent include study , include anaesthetic drug . Patients history malignant tumor past 5 year Patients diagnosis active tuberculosis time recruitment Patients prior positive marker follow pathogen : hepatitis b c , hiv1 hiv2 Patients history clinically relevant hepatic , gastrointestinal , haematological , pulmonary , neurological disease directly relate epidermolysis bullosa . Any medical condition , investigator´s judgment , might interfere optimal participation study involve significant risk patient . Alcoholism , drug addiction , psychiatric disorder , factor present legal guardian , investigator´s judgment may complicate patient participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>